Figure 2: Impact of test-and-treat on severe cases.

No restrictions on access to symptomatic testing at clinics (i.e. all symptomatic individuals who sought testing at clinics would receive one if in stock) and high-risk household contacts of test-positive individuals are not tested. All eligible high-risk individuals (i.e. ≥60 years of age or an adult ≥18 years with a relevant comorbidity) who tested positive were given a course of oral antivirals. Line plots (left $\mathit{y}$-axis) show the percentage change in severe cases relative to no distribution of antivirals under different levels of mean test availability (different shades of color) after a 90-day epidemic wave in a population of 1,000,000 individuals with (a) 10%, (b) 50%, and (c) 90% vaccination coverage for different epidemic intensities (measured by the initial effective reproduction number $\left({\mathit{R}}_{\mathit{e}}\right)$; $\mathit{x}$-axis). Bar plots (right $\mathit{y}$-axis) show the number of severe cases in each corresponding scenario. The dotted outline of each bar shows the number of severe cases of each scenario when no antivirals were distributed.